| Literature DB >> 33008293 |
Huan Zhang1, Xiangtao Li1, Luyuan Niu1, Yaping Feng1, Xiaoyun Luo1, Changming Zhang1, Fuxian Zhang2.
Abstract
BACKGROUND: The iliac occlusive disease is usually treated with endovascular procedures in recent years. The effectiveness of different crossing approaches for these occlusions is not precisely known. We performed a retrospective study to explore the optimal crossing approach (antegrade versus retrograde) for iliac artery chronic total occlusions (CTOs) and to examine the long-term outcomes.Entities:
Keywords: Antegrade approach; Chronic total occlusion; Iliac occlusive disease; Peripheral artery disease; Retrograde approach
Year: 2020 PMID: 33008293 PMCID: PMC7532591 DOI: 10.1186/s12872-020-01715-7
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1a, angiography showing a stump at the proximal end of right common iliac artery and external iliac artery occlusion (arrow); b, successfully antegrade crossing the lesion from contralateral side after the failure of retrograde approach; c, excellent result with stent implantation
Baseline characteristics
| Variables | Total | Antegrade ( | Retrograde ( | |
|---|---|---|---|---|
| Age, mean (SD) | 64.03 ± 11.1 | 64.04 ± 10.7 | 64.02 ± 12.78 | 0.862 |
| Male, | 88 (75.8) | 55 (82.1) | 33 (82.5) | 0.864 |
| Stroke history, | 28 (24.1) | 21 (28.7) | 9 (20.3) | 0.352 |
| MI history, | 22 (18.9) | 12 (16.4) | 8 (18.6) | 0.766 |
| Diabetes, | 37 (31.8) | 24 (32.8) | 10 (23.3) | 0.273 |
| CAD, | 49 (42.2) | 28 (38.4) | 21 (48.8) | 0.273 |
| Hypertension, | 74 (63.7) | 50 (68.5) | 24 (55.8) | 0.171 |
| Dyslipidemia, | 47 (40.5) | 31 (42.5) | 16 (37.2) | 0.578 |
| CHF, | 13 (11.2) | 8 (11.0) | 5 (11.6) | 0.912 |
| Smoking, | 42 (36.2) | 29 (39.7) | 12 (27.9) | 0.198 |
| EGFR, mean (SD) | 83.6 ± 13.02 | 84.55 ± 13.0 | 81.99 ± 13.07 | 0.793 |
| CLI, | 69 (59.4) | 45 (61.6) | 24 (55.8) | 0.537 |
| ALI, | 19 (16.3) | 12 (16.4) | 7 (16.3) | 0.982 |
| Rutherford 3, | 28 (24.1) | 16 (21.9) | 12 (27.9) | 0.446 |
| Rutherford 4–6, | 88 (75.8) | 57 (78.1) | 31 (72.1) | 0.446 |
| ABI, mean (SD) | 0.27 ± 0.21 | 0.25 ± 0.21 | 0.29 ± 0.22 | 0.005 |
| Aspirin ( | 57 (49.1) | 38 (52.1) | 19 (44.2) | 0.413 |
| Clopidogrel ( | 22 (18.9) | 17 (23.3) | 5 (11.6) | 0.122 |
| Statin ( | 37 (31.8) | 23 (31.5) | 14 (32.6) | 0.907 |
ABI Ankle-brachial index, ALI acute limb ischemia, CAD coronary artery disease, CHF congestive heart failure, CLI chronic limb ischemia, EGFR estimated glomerular filtration rate, MI myocardial infarction, SD standard deviation
Angiographic and procedural characteristics
| Variables | Total ( | Antegrade ( | Retrograde ( | |
|---|---|---|---|---|
| CIA, | 14 (12.1) | 5 (6.8) | 9 (20.9) | 0.005 |
| CIA/EIA, | 60 (51.7) | 43 (58.9) | 17 (39.5) | 0.016 |
| EIA, | 42 (36.2) | 25 (34.2) | 17 (39.5) | 0.561 |
| Procedural success, | 113 (97.4) | 71 (97.3) | 42 (97.3) | 0.891 |
| No/mild calcification, | 25 (21.5) | 17 (23.2) | 8 (18.6) | 0.780 |
| Moderate/sever calcification, | 91 (78.4) | 56 (76.7) | 35 (81.3) | 0.531 |
| Target lesion length, mean (SD) | 7.69 ± 2.84 | 8.93 ± 2.37 | 5.58 ± 2.28 | 0.021 |
| TASC C, | 40 (34.4) | 19 (26.0) | 21 (48.8) | 0.013 |
| TASC D, | 76 (65.5) | 54 (74.0) | 22 (51.2) | 0.013 |
| Leichter, | 33 (28.4) | 23 (31.5) | 10 (23.3) | 0.341 |
| Self-expanding stents, | 110 (94.8) | 71 (97.3) | 39 (90.7) | 0.123 |
| Covered stents, | 52 (44.8) | 34 (46.6) | 18 (41.9) | 0.620 |
| Kissing stents, | 12 (10.3) | 7 (9.6) | 5 (11.6) | 0.728 |
| Target lesion complications, | 5 (4.3) | 3 (4.1) | 2 (4.6) | 0.270 |
| Perforation | 1 (0.8) | 0 | 1 (2.3) | 0.191 |
| Dissection | 2 (1.7) | 1 (1.3) | 1 (2.3) | 0.110 |
| Embolism | 2 (3.4) | 2 (2.7) | 0 | 0.274 |
| Atherectomy, | 20 (17.2) | 10 (13.7) | 10 (23.3) | 0.188 |
| Re-entry techniques, | 23 (19.8) | 8 (11.0) | 15 (34.9) | 0.002 |
| Fluoroscopy time, min | 33.6 ± 12.5 | 35.48 ± 12.5 | 30.35 ± 11.87 | 0.509 |
| Subintimal angioplasty | 62 (53.4) | 33 (45.2) | 29 (67.4) | 0.021 |
| pseudoaneurysm | 4 (3.4) | 2 (2.7) | 2 (4.6) | 0.120 |
CIA common iliac artery, EIA external iliac artery, SD standard deviation, TASC TransAtlantic Inter-Society Consensus II
Univariate and Multivariate Logistic Regression Analysis for Association Between Baseline Factors and Subintimal Crossing Approach
| Variables | Univariate | Multivariate |
|---|---|---|
| Calcification | 3.17 (1.01–7.69) | 4.27 (1.19–15.34) |
| Length > 80 mm | 4.23 (1.66–9.45) | 2.96 (1.26–6.97) |
| Final antegrade | 0.22 (0.05–0.52) | 0.34 (0.14–0.84) |
| Smoking | 2.89 (1.03–8.07) | 2.12 (0.56–7.63) |
| TASC | 1.11 (0.49–2.51) | |
| ALI | 1.59 (0.48–5.25) | |
| CLI | 1.78 (0.69–4.60) | |
| CIA | 1.29 (0.39–4.31) | |
| EIA | 1.86 (0.26–13.10) | |
| Sex | 1.36 (0.39–4.68) | |
| Rutherford | 0.92 (0.13–6.36) | |
| Diabetes | 2.20 (0.75–6.42) | |
| Hypertension | 1.13 (0.38–3.33) | |
| Dyslipidemia | 0.75 (0.14–3.98) | |
| Stroke history | 2.45 (0.76–7.91) | |
| MI history | 0.27 (0.04–1.74) | |
| CHF | 1.27 (0.13–12.15) | |
| CAD | 0.93 (0.29–2.94) | |
| Age | 0.96 (0.91–1.01) | |
| ABI | 0.97 (0.09–10.22) | |
| Aspirin | 1.10 (0.33–3.60) | |
| Clopidogrel | 0.80 (0.18–3.57) | |
| Statin | 0.64 (0.10–3.99) |
ABI ankle-brachial index, ALI acute limb ischemia, CAD coronary artery disease, CHF congestive heart failure, CIA common iliac artery, CLI chronic limb ischemia, EGFR estimated glomerular filtration rate, EIA external iliac artery, MI myocardial infarction, TASC TransAtlantic Inter-Society Consensus II
Fig. 2Kaplan-Meier curves of 5-year a primary patency and b major adverse limb events (MALE). There are no significant differences between these two crossing approaches